Patents by Inventor Aaron Almeida
Aaron Almeida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250115907Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.Type: ApplicationFiled: June 17, 2024Publication date: April 10, 2025Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Stacey MELQUIST, Steven KANNER, David B. ROZEMA, David L. LEWIS, Lauren J. ALMEIDA, Darren H. WAKEFIELD, Vladimir S. TRUBETSKOY, Tao PEI, Zhen LI, Aaron ALMEIDA
-
Patent number: 12173086Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.Type: GrantFiled: October 14, 2021Date of Patent: December 24, 2024Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
-
Patent number: 11840688Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: GrantFiled: February 19, 2021Date of Patent: December 12, 2023Assignee: Arrowhead Pharmaceuticals, inc.Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Publication number: 20220024975Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.Type: ApplicationFiled: October 14, 2021Publication date: January 27, 2022Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
-
Patent number: 11180529Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.Type: GrantFiled: April 30, 2019Date of Patent: November 23, 2021Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
-
Publication number: 20210180066Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: ApplicationFiled: February 19, 2021Publication date: June 17, 2021Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Patent number: 10927373Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: GrantFiled: April 16, 2018Date of Patent: February 23, 2021Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Publication number: 20200263179Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.Type: ApplicationFiled: May 6, 2020Publication date: August 20, 2020Inventors: Stacey MELQUIST, Steven KANNER, David B. ROZEMA, David L. LEWIS, Lauren J. ALMEIDA, Darren H. WAKEFIELD, Vladimir S. TRUBETSKOY, Tao PEI, Zhen LI, Aaron ALMEIDA
-
Patent number: 10662427Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.Type: GrantFiled: February 21, 2018Date of Patent: May 26, 2020Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
-
Publication number: 20190248832Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.Type: ApplicationFiled: April 30, 2019Publication date: August 15, 2019Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
-
Publication number: 20180230470Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: ApplicationFiled: April 16, 2018Publication date: August 16, 2018Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Patent number: 10047361Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.Type: GrantFiled: September 27, 2017Date of Patent: August 14, 2018Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
-
Publication number: 20180195070Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.Type: ApplicationFiled: February 21, 2018Publication date: July 12, 2018Inventors: Stacey MELQUIST, Steven KANNER, David B. ROZEMA, David L. LEWIS, Lauren J. ALMEIDA, Darren H. WAKEFIELD, Vladimir S. TRUBETSKOY, Tao PEI, Zhen LI, Aaron ALMEIDA
-
Patent number: 9976141Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: GrantFiled: May 27, 2016Date of Patent: May 22, 2018Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Patent number: 9932586Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.Type: GrantFiled: September 30, 2016Date of Patent: April 3, 2018Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
-
Publication number: 20180023084Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.Type: ApplicationFiled: September 27, 2017Publication date: January 25, 2018Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
-
Patent number: 9803201Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.Type: GrantFiled: March 16, 2016Date of Patent: October 31, 2017Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
-
Publication number: 20170096665Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.Type: ApplicationFiled: September 30, 2016Publication date: April 6, 2017Inventors: Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
-
Publication number: 20160348107Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: ApplicationFiled: May 27, 2016Publication date: December 1, 2016Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Publication number: 20160272971Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.Type: ApplicationFiled: March 16, 2016Publication date: September 22, 2016Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
